Efficacy and safety of durvalumab + chemotherapy vs. atezolizumab + chemotherapy in the treatment of small‑cell lung cancer: a retrospective comparative cohort study

BACKGROUND: Durvalumab and atezolizumab have recently been approved in extensive small cell lung cancer (SCLC) with moderate median overall survival (OS) improvements. However, only limited data exist regarding the impact of immunotherapy in real-world SCLC patients. This study sought to assess the...

Descripción completa

Detalles Bibliográficos
Autores principales: Zou, Yuxia, Ren, Xueru, Zhang, Huanhuan, Wang, Yuenan, Wang, Hanqi, Bai, Rubing, Zhang, Zhihong, Sun, Gengyun, Xu, Ling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10323594/
https://www.ncbi.nlm.nih.gov/pubmed/37426159
http://dx.doi.org/10.21037/jtd-23-588

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10323594/
https://www.ncbi.nlm.nih.gov/pubmed/37426159
http://dx.doi.org/10.21037/jtd-23-588

Ejemplares similares